For someone considering Omzo, the most consequential contract detail is not the advertised starting price. It is the point at which the company considers a prescription order processed: submission of the initial medical intake. Under its terms, that generally makes the order nonrefundable, subject to specified exceptions. That boundary deserves attention before completing enrollment, particularly because the public documentation does not establish how much medication a listed package covers or when another payment would become due.
Omzo presents itself as a telehealth platform connecting adults with outside clinicians for weight care, primarily involving compounded medications. Its pages describe consultations, prescriptions, delivery and ongoing support, but they also contain conflicting statements about branded-drug fulfillment, refund channels and contact addresses. This review examines public documentation consulted October 19, 2026. The central question is whether a prospective customer can understand the purchase, identify the responsible parties and know what happens if treatment or billing does not proceed as expected.
At a glance
- Platform rather than medical practice
- Omzo says it does not employ healthcare providers, operate as a pharmacy or directly provide medication; third-party clinicians decide whether to prescribe.Sources: [7]
- Prices lack a defined billing period
- The homepage advertises semaglutide starting at $179 and tirzepatide starting at $279. The consulted documentation does not establish a comparable monthly cost.
- Early nonrefundability boundary
- Prescription orders are generally considered processed and nonrefundable once the initial medical intake is submitted, with specified exceptions.Sources: [4]
- Cancellation is not a refund
- Canceling a subscription after a processed charge prevents future charges, according to the terms, but does not refund that charge.Sources: [4]
- Dispatch, not arrival
- The terms say compounded medication will ship within the next 48 business hours after prescription approval; they do not promise arrival within that period.Sources: [4]
The first commitment happens before shipment
Omzo's prescription refund language places the important transaction boundary at submission of the initial medical intake—not at receipt of medication. The company says an order is then processed and nonrefundable because medical and pharmacy resources are used for provider review, prescription processing and shipping logistics. Specified exceptions remain available, but the general rule makes the intake more than an expression of interest. A prospective customer should understand the applicable charge and package before submitting it.
The terms separately address subscriptions. If cancellation occurs after a charge has been processed, it prevents future charges but does not reverse the processed payment. The consulted pages do not explain the practical cancellation procedure, required advance notice, renewal frequency or minimum commitment. They therefore support neither a claim that Omzo is freely cancelable at any moment without financial consequences nor a claim that every purchase carries a particular long-term obligation.
Supplement purchases have another boundary: the terms consider them processed and nonrefundable once payment is made. Omzo attributes that rule to products being tailored to individual plans and unsuitable for restocking or reuse. Customers considering medication and supplements together should ask which items are included and which transaction rules apply. Our guide to cancellation notice and order status explains why stopping future billing and reversing an existing order are separate questions.
The quoted prices do not define a monthly contract
Omzo's homepage advertises semaglutide starting at $179 and tirzepatide starting at $279. Its terms use different package labels and distinguish initial from follow-up consultations. Crucially, the quoted prices do not establish a supply period, quantity or billing interval. The exact formulation, concentration, presentation and route that would be dispensed are also not established by these descriptions. Treating any of these figures as a recurring monthly medication price would add information the documents do not provide.
The initial-package language says “originally priced,” which is not the same as an unqualified current checkout price. Tirzepatide also has an unresolved difference between the homepage's starting-at $279 offer and the terms' originally priced $259 initial package. The GLP-1 package does not identify its medication as precisely as the GLP-1 + GIP package, which names compounded tirzepatide. A written quote should resolve both the product and the applicable price rather than assuming the labels are interchangeable.
Omzo says medication costs are included in fees it collects and that it pays the pharmacies. The listed packages also include consultation, prescription, shipping and ongoing medical support if needed. Transactions are in U.S. dollars; listed cards are MasterCard, Visa, American Express and Discover. Omzo says it does not store card details. Promotion-specific terms may apply. None of this establishes insurance billing, HSA/FSA acceptance or a renewal schedule; our billing commitments guide explains that distinction.
| Offer or package | Published price wording | Included services or unresolved boundary |
|---|---|---|
| Homepage semaglutide | Starting at $179 | Supply period, exact dispensed product and commitment are not defined. |
| Homepage tirzepatide | Starting at $279 | Relationship to the initial package in the terms is unresolved. |
| Initial GLP-1 consultation | Originally priced at $179 | Consultation, prescription, GLP-1 medication, shipping and support if needed; supply duration unspecified. |
| Follow-up GLP-1 consultation | Priced at $299 | Same listed service categories; billing interval unspecified. |
| Initial GLP-1 + GIP consultation | Originally priced at $259 | Compounded tirzepatide, consultation, prescription, shipping and support if needed; supply unspecified. |
| Follow-up GLP-1 + GIP consultation | Priced at $399 | Compounded tirzepatide and listed services; supply period and recurrence unspecified. |
Refund exceptions exist, but the request channel conflicts
Omzo provides a full-refund exception when a medical provider determines during the initial consultation that a patient is not medically eligible. That exception has a significant qualification: it does not apply when a disqualifying condition was knowingly omitted or misrepresented in the initial questionnaire, as evidenced by contradictions with consultation disclosures. This is a specific exception to the general nonrefundability rule, not a broad satisfaction guarantee or an assurance that every unsuccessful enrollment will be reimbursed.
A separate full-refund provision covers processing mistakes by Omzo, including duplicate or incorrect charges. Requests must be made within 28 days of the original payment date. The channel instructions conflict: one passage permits a written request by email or physical mail, while another says requests through channels other than email will not be honored. The consulted text does not resolve that inconsistency or establish a timetable for funds to reach a customer's bank.
The practical preparation is to obtain a usable refund email address and clarification of the accepted submission method before paying. Email addresses in the consulted material were obscured, so this review cannot reproduce a functioning address. Keep the payment date, receipt, relevant questionnaire records and written correspondence available if a dispute arises. Our explanation of refund guarantees and exclusions provides context for reading a narrow refund exception without mistaking it for a general right to reverse a purchase.
Enrollment passes from Omzo to an outside clinician
Omzo's privacy notice identifies the business as Omzo Inc. Its general disclosures say it is not a medical practice or pharmacy, does not employ healthcare providers and does not directly provide medication. Instead, third-party networks of U.S.-licensed clinicians assess medical history and determine whether to prescribe. These are Omzo's descriptions of its arrangement, not independent verification of an individual clinician's credentials. The consulted pages do not identify the networks, treating professionals or dispensing pharmacies by name.
The privacy notice describes a handoff: Omzo collects initial qualifying information and passes it to relevant healthcare providers. If appropriate, a provider invites the person to schedule an initial appointment through a provider-operated patient portal, not an Omzo-operated portal. The provider then requests additional medical information and supplies diagnosis, consultation and treatment. Omzo also states that its website assessment does not itself create a doctor–patient relationship. Completing the form therefore should not be confused with receiving a clinical evaluation.
Services are intended for adults 18 and older. The terms restrict products and services to the 50 U.S. states, excluding other territories and countries, but that commercial boundary does not establish actual clinician availability in every state. Detailed eligibility criteria and appointment timelines remain undocumented. Before submitting an intake, identify who will provide care, where that clinician can treat patients and who handles a stalled referral. The platform, clinician and pharmacy responsibility guide offers a framework for those questions.
Compounded treatment and branded prescriptions have different boundaries
Omzo describes its primary program as access to compounded medication prepared and shipped by a state-licensed sterile compounding pharmacy. It also says the preparations are produced in FDA-registered facilities. Those are provider statements, not independently verified licensing or registration findings. Facility registration is not product approval. Omzo's terms acknowledge that compounded drugs are not FDA approved and that FDA does not review them for safety, efficacy or quality; Omzo also disclaims equivalence and identical clinical outcomes relative to approved drugs.
FDA recommends compounded drugs when an individual's medical needs cannot be met by an FDA-approved drug, with a prescription and a state-licensed pharmacy. Nonapproval alone does not establish clinical inequivalence, but it also does not validate a preparation. For enrollment purposes, the missing product details matter: the consulted documentation does not establish the exact formulation, concentration, presentation or route of each medication. The homepage also advertises custom daily oral medication kits without identifying their active ingredients in the consulted description.
Branded medication creates a separate contractual contradiction. The general notice says Omzo does not sell, dispense or ship branded drugs; patients must fill prescriptions at their chosen pharmacy and bear associated costs. The terms nevertheless describe limited exceptions in which Omzo manages branded-drug dispensing and shipping, subject to clinical approval and inventory. Both versions place branded-drug costs on the patient. Anyone pursuing that route should obtain written confirmation of the applicable pharmacy channel, fulfillment arrangement and separate charges.
Shipping promises stop short of a delivery guarantee
After prescription approval during the telehealth consultation, Omzo's terms say compounded medication will be shipped within the next 48 business hours. That is a dispatch statement, not a promised arrival date, and it does not establish how quickly the consultation or prescription review occurs. The homepage advertises free, discreet delivery on all treatments and plain packaging. Free shipping does not mean free treatment, and it does not resolve the conflicting branded-medication fulfillment descriptions elsewhere on the site.
The terms state that shipping cannot be canceled or modified after dispatch. This is distinct from the earlier financial boundary at intake submission: an order can become generally nonrefundable before the shipment becomes unchangeable. Confirming an address and the applicable shipping arrangements early is therefore useful. The consulted pages do not identify a carrier, tracking process, cold-chain procedure, replacement policy for loss or damage, or delivery deadline. The review cannot fill those gaps with assumptions about ordinary pharmacy practice.
A delivery problem can also require clinical or pharmacy action rather than only a billing inquiry. FDA explicitly advises not using an injectable GLP-1 product that arrives warm or with insufficient refrigeration, and contacting the provider or dispensing pharmacy. That guidance is not evidence that Omzo deliveries have experienced such problems. It does make a reachable pharmacy contact and clear problem-resolution process important information to obtain before shipment, especially when the public documentation does not name the dispensing pharmacy.
Included support is described broadly, not operationally
The package terms include ongoing medical support “if needed,” while the homepage advertises clinician-reviewed treatment plans, messaging access to an Omzo care team and ongoing support through the Omzo app. Those statements document an advertised support offering, but not a response-time commitment or a defined clinical follow-up schedule. They also do not identify which messages reach a clinician rather than platform staff. The distinction matters when a customer needs treatment advice, a prescription review or help with a charge.
Omzo says plans may include clinician-prescribed medication, nutrition guidance and daily habits focused on long-term balance. “May include” should not be read as a guarantee that every package contains every component. The homepage additionally mentions supplements delivered to the home. Before accepting a package, ask whether supplements are included, optional or separately charged, and whether follow-up consultation pricing applies to each review. The consulted documentation does not establish a cadence that would connect the follow-up package prices to a predictable billing calendar.
NIDDK describes medication follow-up as attention to response and tolerability, not simply continued payment. That clinical context does not prove how Omzo's outside networks conduct follow-up, but it helps distinguish a useful care commitment from a general support promise. A prospective customer can ask who assesses progress, how questions are escalated and what happens if a clinician does not recommend continuing. The public terms do not establish those operational details or a general refund entitlement for later treatment changes.
Contact and privacy details need confirmation before payment
Omzo publishes conflicting street numbers for its Lewes, Delaware address. The contact page lists 6192 Coastal Highway, Lewes, DE 19958; the HIPAA policy lists 16192 Coastal Highway, Lewes, Delaware 19958, County of Sussex. The latter also provides (332) 301-2274. This review cannot determine which street number should be used for correspondence. The discrepancy matters particularly because the refund instructions mention physical mail before separately rejecting non-email submissions. A telephone listing is not confirmation that telephone refund requests are accepted.
The privacy notice directs users to provide health or medical information only through healthcare-provider sites after completing Omzo's initial brief questionnaire. Its consumer-health-data language also contemplates use for services, advertising and marketing, and legal matters, subject to applicable law and consent where required. These statements deserve a separate read from treatment and price descriptions. A customer should know which portal receives medical records and where a billing question can be sent without unnecessarily including additional health information.
The HIPAA policy's treatment and “patient of Omzo” language also sits uneasily beside statements that Omzo does not diagnose or treat and that outside providers deliver clinical services. The documentation does not resolve that difference in role descriptions. Before enrollment, request one written account of the contracting business, treating network, pharmacy, payment schedule, cancellation route and refund contact. That would address the most consequential documentary gaps without assuming that an inconsistency proves misconduct or that a polished enrollment experience resolves it.
Questions & answers
Is Omzo's $179 semaglutide offer a monthly price?
The consulted homepage says “starting at $179,” but does not define a monthly supply or recurring monthly charge. Separately, the terms describe an initial GLP-1 package as originally priced at $179 and a follow-up package at $299. Neither description establishes the supply period. Ask for the current product-specific charge, quantity covered and next billing date rather than treating these figures as a monthly subscription quote.
Can I get a refund if Omzo's clinician says I am not eligible?
The terms provide a full refund when the provider determines during the initial consultation that the patient is not medically eligible. The exception does not apply if a disqualifying condition was knowingly omitted or misrepresented in the initial questionnaire under the stated conditions. Refund requests have a 28-day deadline from payment, and the conflicting submission instructions should be clarified. This is not a general satisfaction guarantee.
Does canceling an Omzo subscription reverse the latest charge?
Not under the general rule described in the terms. Cancellation after a processed charge prevents future charges, but previously processed charges remain nonrefundable, subject to the stated exceptions. The consulted documentation does not provide a practical cancellation method, renewal interval or advance-notice requirement. Obtain those details before paying, and distinguish confirmation that a subscription has ended from confirmation that a particular payment will be refunded.
Will Omzo fill and ship a branded GLP-1 prescription?
The public descriptions conflict. The general notice says patients fill branded prescriptions at their chosen pharmacy and pay all associated costs. The terms describe limited exceptions allowing Omzo-managed dispensing and shipping, depending on clinical approval and inventory. Neither version guarantees availability, and both assign branded-drug costs to the patient. Ask which arrangement applies to your transaction and do not assume a compounded-medication package price covers a branded prescription.
How quickly does Omzo promise medication will arrive?
It does not establish an arrival deadline in the consulted documentation. The terms say compounded medication will ship within the next 48 business hours after prescription approval during the telehealth consultation. They also prohibit shipment cancellation or modification after dispatch. Carrier, tracking, temperature-handling and replacement details remain undocumented. Confirm those arrangements with the responsible provider or pharmacy rather than interpreting the dispatch statement as a delivery guarantee.
Does Omzo provide medical care directly?
Omzo says it is not a medical practice, does not employ healthcare providers and does not diagnose or treat conditions. Its described process sends initial information to outside providers, who may invite the user into their own portal for evaluation and care. The website assessment alone does not create a doctor–patient relationship. Because the consulted pages do not name those networks, request the treating organization's identity and clinical contact route before proceeding.
Our assessment
Omzo documents several useful purchase terms: bundled service categories, distinct initial and follow-up prices, specific refund exceptions, and a separation between platform and clinical decision-making. Its limitations are equally material. Public documentation does not establish a comparable monthly cost, supply duration, renewal calendar or practical cancellation procedure, while conflicting branded-drug, contact and refund-channel statements complicate accountability. The early nonrefundability boundary makes resolving those questions before intake especially important. A written, product-specific quote and clear contacts for the clinician, pharmacy and billing team would materially improve decision preparation. Contract clarity would not itself establish clinical quality or outcomes, but it would make the financial commitment and service responsibilities easier to evaluate.
This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.
Sources & documentation
Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.